All News

The NALIRIFOX regimen of Onivyde plus 5-fluorouracil/leucovorin and oxaliplatin has been shown to have survival and disease progression benefits for patients with pancreatic cancer in a clinical trial setting.

Factors including race, insurance and treatment history have been associated with increased cardiovascular disease, risk factors and mortality among cancer survivors, including those with a history of pediatric cancer, according to recent research.

Surviving cancer means not just checking items off a bucket list, but also taking pleasure in doing the mundane, from sweeping a porch to mowing a lawn.

From Martina Navratilova's latest cancer update to the death of the Pentagon Papers whistleblower, here's what's happening in the oncology space this week.

After two years of follow-up, patients with advanced melanoma treated with Opdivo and Opdualag continued to obtain a survival benefit compared with Opdivo alone.

The addition of Tecentriq to Cabometyx did not improve the length of time patients lived without their disease getting worse for individuals with previously treated advanced kidney cancer, and came with additional side effects, too, recent research showed.

Here are a series of poems written about our ordeal with cancer and kicking it to the curb.

After two diagnoses of acute myeloid leukemia, intense chemo and a bone marrow transplant, I’ve learned some things that helped me along the way.

Musician Andrew McMahon has made it his mission to spread the message of community and seeking mental health care like therapy for adolescents and young adults with cancer.

The full approval is based on data showing that 80% of patients with B-ALL experienced a complete MRD response.

Most cancer memories are triggering for me, but one place is particularly sweet when I think back on it.

Adding Cabometyx to Opdivo and Yervoy tended to improve progression-free survival in patients with advanced kidney cancer, research showed.

Jaktinib significantly improved spleen volume reduction rates compared with hydroxyurea in intermediate- to high-risk myelofibrosis.

The combination of Talzenna and Xtandi was approved for the treatment of adults with HRR gene-mutated metastatic castration-resistant prostate cancer.

Patients with platinum-resistant or refractory ovarian cancer experienced deep responses and survival benefits in a trial assessing immunotherapy with chemotherapy.

We asked our audience what life hacks they learned to make cancer treatment a bit easier. Here’s what they had to say.

After being diagnosed with an incurable cancer, I had to reframe my thinking to focus on the positive.

An expert discusses the ongoing SPARK trial for KRASG12-mutant non-small cell lung cancer, and what she hopes for the future of this patient population.

Watch Dr. Rami Komrokji and Dr. John O. Mascarenhas answer questions about myelofibrosis during the CURE® Educated Patient® MPN Summit.

Patients with a subtype of lymphoma may be able to exclude radiotherapy if they respond to chemoimmunotherapy, although more follow-up is needed to assess potential long-term toxicities.

Here’s an overview of the new cancer regimens that gained Food and Drug Administration (FDA) approval in the spring of this year.

I learned that finding the right kind of support during and after a cancer diagnosis is truly invaluable.

Researchers are looking for other ways to disrupt tumor cells in a way that better engages the immune system by exposing it to tumor antigens.

Watch Dr. John O. Mascarenhas, from Icahn School of Medicine, discuss novel therapies in myelofibrosis during the CURE® Educated Patient® MPN Summit.

Watch Dr. Rami Komrokji, from Moffitt Cancer Center, discuss risk stratification and management of myelofibrosis during the CURE® Educated Patient® MPN Summit.

While my taste buds have returned to normal after cancer treatment, my desire to cook and eat has not.

Watch Dr. Nikolai Podoltsev, Dr. Jerry Spivak and Amy Lane answer questions about polycythemia vera during the CURE® Educated Patient® MPN Summit.

A significant majority of patients with early-stage classical Hodgkin lymphoma demonstrated a complete response to treatment with Adcetris, Opdivo and chemotherapy.